ANKYLOSING SPONDYLITIS

ANKYLOSING SPONDYLITIS

Ankylosing Spondylitis (AS), a form of spondylarthritis (SpA), is a systemic inflammatory rheumatic disease. Although the exact pathogenesis of AS is not yet fully understood, as with rheumatoid arthritis, the swelling, pain, and joint damage that characterize AS are considered to be the result of complex autoimmune and inflammatory processes based on both environmental and genetic factors.

IAG’s team has extensive expertise and track record in supporting the development of novel therapeutics in AS and SpA and helping to take these drugs from early phase all the way to phase 3 and approval. Our expertise is in use of

  • X-ray
  • MRI
  • Dynamic Contrast Enhanced MRI
  • CT

to support disease diagnosis and assessment of treatment response.

IAG’s team plays an active role in the scientific community and have led the development of novel scoring systems for early assessment of synovial inflammatory changes, quantification of inflammation and quantitative assessment of erosive changes. Our extensive experience in using radiography, which is a conventional gold standard method for assessment of structural damage in spine and sacroiliac joints. Our medical science team have worked with drug developers in trials incorporating Computed Tomography (CT), which is a more sensitive method for assessment of structural changes in the spine and sacroiliac joints.

In many trials, early diagnosis of sacroiliitis, the most frequent clinical symptom often accompanied by inflammatory back pain, and other inflammatory lesions of the spine such as spondylitis and spondylodiscitis, can be visualized early by magnetic resonance imaging (MRI), especially using fat saturating STIR or Gd-Enhanced Dynamic MRI sequences. IAG’s team helped to integrate ultrasonography and MRI into the trials for visualization and quantification of peripheral arthritis and enthesitis.

 

About IAG, Image Analysis Group

IAG, Image Analysis Group is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development, and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed.

Contact our expert team: imaging.experts @ ia-grp.com

READ NEXT CASE STUDY >
Experience: Scoring Systems
  • New York criteria
  • Stoke Ankylosing Spondylitis Spinal Score (SASSS)
  • Bath Ankylosing Spondylitis Radiology Index (BASRI)
  • MRI Spine Score
Experience: Imaging
  • MRI
  • DCE-MRI
  • X-ray
  • CT
  • US
Publications

Since 2007, over 2000 articles were published to cover scientific discoveries, technology break-throughs and special cases. We list here some critically important papers and abstracts.

Testimonials

Combining our technologies and business advisory services with promising life science companies has yielded spectacular results over the past five years. As a trusted partner to many biotech and pharma companies, IAG’s team is proud to share your words and quotes.